ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2019
Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03113110. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Empagliflozin in Post-Transplantation Diabetes Mellitus
Open the trial in the graphWho cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Blood pressure effects of SGLT2 inhibitors in kidney transplant recipients: a systematic review and meta-analysis.International urology and nephrology · 2026Pooled it
- The Efficacy and Safety of SGLT2 Inhibitors in Diabetes Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.F1000Research · 2025Pooled it
- Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.The Cochrane database of systematic reviews · 2020Pooled it
- Clinical value of adding Dapagliflozin in patients with nephrotic syndrome.International urology and nephrology · 2024Trial
- Safety of SGLT2 inhibitors in patients with different glomerular diseases treated with immunosuppressive therapies.European journal of clinical pharmacology · 2023Trial
- Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.Cardiovascular diabetology · 2021Trial
- Article
- The Potential Role of SGLT2 Inhibitors in Cushing's Disease.Diabetes, obesity & metabolism · 2026Review
- Early safety observations of peri-transplant SGLT2 inhibitor use in lung transplant recipients.Journal of thoracic disease · 2026Article
- Effects of SGLT2 Inhibitors on Proteinuria and Renal Function Parameters in Non-Diabetic Kidney Transplant Recipients: A Retrospective Cohort Study Based on 12-Month Follow-Up Data.Journal of clinical medicine · 2026Article
- Randomized Controlled Trial of Dapagliflozin for Post-Transplant Diabetes Mellitus in Renal Transplant Recipients.Kidney international reports · 2026Article
- Article
- Finerenone as a Third-Line Therapy for Persistent Proteinuria in Diabetic Kidney Transplant Recipients.International journal of molecular sciences · 2026Observational
- Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus.Journal of clinical medicine · 2025Article
- Expanding the Therapeutic Landscape: Sodium-Glucose Co-transporter 2 Inhibitors in Kidney Transplant Recipients.Cureus · 2025Review
- Diabetes Mellitus in Kidney Transplant Recipients and New Hypoglycemic Agent Options.International journal of molecular sciences · 2025Review
- Empagliflozin as treatment in glycogen storage disease type IB patients.Molecular genetics and metabolism reports · 2025Article
- Dapagliflozin's Effects on Urinary Albumin and Non-Albumin Proteins in Diabetic and Non-Diabetic Kidney Transplant Recipients.Biomedicines · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The safety and efficacy of sodium-glucose cotransporter 2 inhibitors in posttransplantation diabetes mellitus is unknown. We converted stable kidney transplant patients to 10 mg empagliflozin, aiming at replacing their insulin therapy (<40 IU/d). N = 14 participants (the required sample size) completed the study visits through 4 weeks and N = 8 through 12 months. Oral glucose tolerance test (OGTT)-derived 2-hour glucose (primary end point) increased from 232 ± 82 mg/dL (baseline) to 273 ± 116 mg/dL (4 weeks, P = .06) and to 251 ± 71 mg/dL (12 months, P = .41). Self-monitored blood glucose and hemoglobin A1c were also clinically inferior with empagliflozin monotherapy, such that insulin was reinstituted in 3 of 8 remaining participants. Five participants (2 of them dropouts) vs nine of 24 matched reference patients developed bacterial urinary tract infections (P = .81). In empagliflozin-treated participants, oral glucose insulin sensitivity decreased and beta-cell glucose sensitivity increased at the 4-week and 12-month OGTTs. Estimated glomerular filtration rate and bioimpedance spectroscopy-derived extracellular and total body fluid volumes decreased by 4 weeks, but recovered. All participants lost body weight. No participant developed ketoacidosis; 1 patient developed balanitis. In conclusion, although limited by sample size and therefore preliminary, these results suggest that empagliflozin can safely be used as add-on therapy, if posttransplant diabetes patients are monitored closely (NCT03113110).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.